Specializing in skin care products including globally renowned foot creams and facial creams, Laboratoires Asepta has succeeded in distributing internationally to more than 60 countries on five continents. With more than 100 distributors catering to Asepta’s products, including Akileine, Ecrinal, Coup D’Eclat and Vita Citral, these well-known brands have now achieved an international presence. Intimately linked to the Principality of Monaco, Asepta connects its history to the Monte-Carlo Casino, where in the 1930s croupiers presented a request for foot treatments to sooth soreness after hours of standing work. Thus the first products of Asepta were developed, expanding into a product portfolio remedying a wide variety of dermatological ailments. Committed to using only the most effective active ingredients in their products, developers at Asepta carefully monitor the origin and quality of raw materials to ensure top dermatological safety and standards.
Contact
Phone: +377 92 05 75 51
3 Avenue Albert II, 98000 Monaco
Asepta is medium-sized dermatology company based in Monaco with a 76-year history. Its CEO, Anne Marie Noir, shares the success stories the company has experienced in international markets, the challenges…
Anne-Marie Noir discusses footcare, Laboratoires Asepta’s corporate values, the strategic development behind their innovative brand, and the company’s positioning in Monaco. She also discusses her family’s legacy in the business…
As president of the French League Against Cancer, Dr Daniel Nizri highlights the organization’s 106-year legacy of fighting cancer through research funding, health promotion, patient support, and advocacy. He discusses…
After offloading its consumer healthcare division in 2022 and in view of the gradual erosion of its top seller, Somatuline, Ipsen opted to aggressively seek external assets to enrich its…
France is the third most significant clinical research destination in Europe, participating in 50 percent of the trials initiated across the continent. While favourable government policies and unique strengths such…
Hubert Mechin, president of AFCROs, the association that groups clinical research organisations in France, details the organisation’s efforts to help its members stay abreast of changes in the European regulatory…
With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination…
Just five months after taking office, Aurélien Rousseau resigned from his role as health minister in protest against France’s recently adopted immigration law. Interim replacement Agnès Firmin Le Bodo, the…
France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has…
The latest news from French healthcare and pharma, including an update on the hospital crisis; MaaT Pharma and Skyepharma’s new cGMP microbiome facility; Sanofi’s offloading of central nervous system drugs…
In the French government’s recent cabinet reshuffle, prime minister Elisabeth Borne’s former chief of staff, Aurélien Rousseau was appointed as the new minister of health. Rousseau, having piloted the Île-de-France…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
Despite an uncertain macro-economic environment, the French health technology sector continues its growth trajectory, demonstrating both entrepreneurial dynamism and maturity, according to the new edition of the France Biotech study…
The latest news from French pharma, including fears of medicine shortages and suspension of online sales of paracetamol, CARMAT’s artificial heart product entering a study in France, Sanofi’s expanded deal…
See our Cookie Privacy Policy Here
